"Progress is good, and the patient seems to have made a full recovery, with no neural effects that we are aware of. The patient is able to move a mouse around the screen by just thinking," Musk stated.

Musk added that Neuralink is currently focusing on maximizing the number of mouse button clicks the patient can achieve.

Neuralink successfully implanted a chip on its first human patient last month after gaining approval for human trial recruitment in September.

The study uses a robot to surgically place a brain-computer interface implant in the brain region that controls the intention to move. The initial goal is to enable people to control a computer cursor or keyboard using their thoughts.

Musk envisions grand applications for Neuralink, stating that it could allow for rapid surgical insertions of its chip devices to treat conditions such as obesity, autism, depression, and schizophrenia.

However, the company has faced strong backlash from critics concerned over ethical issues regarding autonomy, long-term health uncertainty, an increased dependence on technology, and the social implications of radically altering societal norms and values.

Neuralink, which was valued at around USD 5 billion last year, has faced ongoing scrutiny concerning its safety protocols. Reuters reported last month that the firm was fined for violating U.S. Department of Transportation rules concerning the movement of hazardous materials.